Advair vs. Pulmicort
See how Advair and Pulmicort compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Advair combines a steroid and a long-acting bronchodilator to treat both asthma and COPD, while Pulmicort is a steroid-only inhaler approved only for asthma.
Both inhalers are taken twice daily for long-term control and are not meant to relieve a sudden asthma or COPD flare-up.
Advair carries a LABA-related warning about increased asthma-related death risk, while Pulmicort's most common side effect is nasopharyngitis, reported in up to 9.3% of users.
Advair vs. Pulmicort Drug Summary
Advair
Advair combines an inhaled corticosteroid and a long-acting bronchodilator in one twice-daily inhaler. It's approved for long-term asthma control in people 4 and older and for managing airflow obstruction and exacerbations in COPD. It is not meant for sudden asthma or COPD attacks.
Pulmicort
Pulmicort is an inhaled corticosteroid taken twice daily through a dry powder inhaler to prevent asthma symptoms over time. It's approved for maintenance asthma treatment in people 6 and older and works by reducing airway inflammation. It does not treat COPD and is not for sudden breathing emergencies.
Advair vs. Pulmicort Side Effects
Advair
Pulmicort
Advair vs. Pulmicort Dosage
Advair
Pulmicort
| STAGE | DOSE | WHEN |
| Starting dose | 100 mcg/50 mcg twice daily | At the start |
| Maximum dose | 500 mcg/50 mcg twice daily | If needed |
| Dose changes | 2 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 180 mcg twice daily | At the start |
| Maximum dose | 720 mcg twice daily | If needed |
| Dose changes | 2 increases | As tolerated |
Advair
| STAGE | DOSE | WHEN |
| Starting dose | 100 mcg/50 mcg twice daily | At the start |
| Maximum dose | 500 mcg/50 mcg twice daily | If needed |
| Dose changes | 2 increases | As tolerated |
Pulmicort
| STAGE | DOSE | WHEN |
| Starting dose | 180 mcg twice daily | At the start |
| Maximum dose | 720 mcg twice daily | If needed |
| Dose changes | 2 increases | As tolerated |
Advair vs. Pulmicort Indications
Advair
Advair treats both asthma and COPD by combining a steroid that reduces airway inflammation with a bronchodilator that keeps airways open. It's approved for long-term control, not for rescue use during an attack, and can also lower the frequency of COPD flare-ups.
Asthma maintenance in patients 4 years and older
COPD maintenance treatment for airflow obstruction
Reduces exacerbations in patients with a history of COPD flare-ups
Not for acute bronchospasm or status asthmaticus
Pulmicort
Pulmicort is used solely for long-term asthma control by lowering airway inflammation over time. It's FDA-approved for people 6 and older, and some doctors also prescribe it off-label for eosinophilic esophagitis. It does not treat COPD and isn't meant for sudden breathing emergencies.
Asthma maintenance in patients 6 years and older
Off-label use for eosinophilic esophagitis (not FDA-approved)
Not approved for children under 6 with Flexhaler
Not for acute bronchospasm or status asthmaticus
Advair vs. Pulmicort Pros and Cons
Advair
Advair's dual-action formula makes it a broader option, covering both asthma and COPD in one device. That versatility comes with an added LABA safety warning and a slightly more complex side-effect profile than a steroid-only inhaler.
Pros
Treats both asthma and COPD, unlike Pulmicort
Combines two mechanisms in one inhaler, simplifying treatment
Available as a lower-cost generic (Wixela Inhub)
FDA-approved specifically for reducing COPD exacerbations
Cons
Carries a LABA-related warning for asthma-related death risk
Not approved for children under 4
Combination therapy may be more than mild asthma requires
Contains two active ingredients, so more potential side effects to monitor
Pulmicort
Pulmicort's steroid-only design keeps its side-effect profile simpler and extends its approval down to younger children. The tradeoff is that it doesn't address COPD and lacks the added bronchodilator some asthma patients need.
Pros
Steroid-only formula may have a simpler side-effect profile
Approved for children as young as 6 with Flexhaler
Also available as a nebulized suspension for younger children
Sometimes used off-label for eosinophilic esophagitis
Cons
Not approved for COPD treatment
No bronchodilator, so may need to be paired with other medication
Flexhaler version not approved for children under 6
Higher reported rate of nasopharyngitis than Advair's respiratory effects
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.